Literature DB >> 8242901

Systemic and mucosal IgA responses to systemic antigen challenge in IgA nephropathy.

L Layward1, A M Finnemore, A C Allen, S J Harper, J Feehally.   

Abstract

IgA nephropathy (IgAN) is characterized by the deposition of glomerular IgA. The source of the deposited IgA is not known, but both the mucosal and systemic IgA systems have been implicated. In order to investigate mucosal and systemic antibody production to systemic antigen challenge in IgAN, 20 patients and 20 controls where immunized with tetanus toxoid (TT). While patients with IgAN responded with a similar serum IgG, IgA, IgA1, and IgA2 antibody response to controls, they did, however, produce more IgA1 antibodies relative to IgA2 (P < 0.05). No salivary IgA antibody response was observed to systemic immunization in controls; however, there was a significant IgA response to TT in the saliva of patients with IgAN. IgA antibodies were produced in vitro by Epstein Barr virus (EBV)-transformed peripheral blood lymphocytes (PBLs) obtained from control blood only when taken shortly (1 or 2 weeks) after immunization. Patients with IgAN produced significantly more IgA anti-TT positive cultures than controls and for a longer period (P < 0.01) after immunization. In contrast, IgG anti-TT was produced in EBV-transformed cultures at all time points, but with no difference between IgAN and controls in the proportion of IgG producing cultures. These results demonstrate increased IgA antibody production in both the systemic and mucosal IgA systems following systemic immunization in IgAN and suggest an abnormal overlap between the two systems in IgAN.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8242901     DOI: 10.1006/clin.1993.1185

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  8 in total

1.  Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA.

Authors:  S J Harper; A C Allen; J H Pringle; J Feehally
Journal:  J Clin Pathol       Date:  1996-01       Impact factor: 3.411

2.  A systematic review and meta-analysis of the IgA seroprevalence in COVID-19 patients: Is there a role for IgA in COVID-19 diagnosis or severity?

Authors:  Velia Verónica Rangel-Ramírez; Karen Alondra Macías-Piña; Roberto Raúl Servin-Garrido; David R de Alba-Aguayo; Leticia Moreno-Fierros; Nestor Rubio-Infante
Journal:  Microbiol Res       Date:  2022-06-30       Impact factor: 5.070

3.  Interactions of sexual activity, gender, and depression with immunity.

Authors:  Tierney Lorenz; Sari van Anders
Journal:  J Sex Med       Date:  2013-02-28       Impact factor: 3.802

4.  Secretory immunoglobulin A (IgA) responses in IgA nephropathy patients after mucosal immunization, as part of a polymeric IgA response.

Authors:  J W Eijgenraam; B D Oortwijn; S W A Kamerling; J W de Fijter; A W L van den Wall Bake; M R Daha; C van Kooten
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

Review 5.  Pathogenetic significance of aberrant glycosylation of IgA1 in IgA nephropathy.

Authors:  Ichiei Narita; Fumitake Gejyo
Journal:  Clin Exp Nephrol       Date:  2008-04-12       Impact factor: 2.801

6.  Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy.

Authors:  Jing Wang; Robert A Anders; Qiang Wu; Dacheng Peng; Judy H Cho; Yonglian Sun; Reda Karaliukas; Hyung-Sik Kang; Jerrold R Turner; Yang-Xin Fu
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

Review 7.  Pathological role of tonsillar B cells in IgA nephropathy.

Authors:  Yusuke Suzuki; Hitoshi Suzuki; Junichiro Nakata; Daisuke Sato; Tadahiro Kajiyama; Tomonari Watanabe; Yasuhiko Tomino
Journal:  Clin Dev Immunol       Date:  2011-07-18

Review 8.  Genetics and immunopathogenesis of IgA nephropathy.

Authors:  Hsin-Hui Yu; Kuan-Hua Chu; Yao-Hsu Yang; Jyh-Hong Lee; Li-Chieh Wang; Yu-Tsan Lin; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 10.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.